EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

María Presa iD, David Vicente, Antonio Calles, Laura Salinas-Ortega iD, Jaesh Naik, Luis F García, Javier Soto iD

ClinicoEconomics and Outcomes Research · 2023-09 · Volume 15 · 659-671

DOI: 10.2147/ceor.s415711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2023-09. Verfasst von María Presa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics, Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

ALK+advanced non-small cell lung cancercost-effectiveness analysiscost-utility analysislorlatinib

Autor:innen und Institutionen

  • Health Economics, Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario Virgen de Macarena, Sevilla, Spain.
  • Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
  • Health Economics, BresMed Health Solutions, Sheffield, UK.
  • Oncology Medical, Pfizer, Madrid, Spain.
  • Health Economics & Outcomes Research, Pfizer, Madrid, Spain.

ORCID-Profile: María Presa, Laura Salinas-Ortega, Javier Soto

Zitieren

APA

Presa, M., Vicente, D., Calles, A., Salinas-Ortega, L., Naik, J., García, L. F., & Soto, J. (2023). Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. ClinicoEconomics and Outcomes Research, Volume 15, 659-671. https://doi.org/10.2147/ceor.s415711

Vancouver

Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, et al. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. ClinicoEconomics and Outcomes Research. 2023;Volume 15:659-671. doi:10.2147/ceor.s415711

BibTeX
@article{Presa2023,
  author = {Presa, María and Vicente, David and Calles, Antonio and Salinas-Ortega, Laura and Naik, Jaesh and García, Luis F and Soto, Javier},
  title = {Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain},
  journal = {ClinicoEconomics and Outcomes Research},
  year = {2023},
  volume = {Volume 15},
  pages = {659--671},
  doi = {10.2147/ceor.s415711}
}
Kostenlos starten →